Our focus is patients, 
Our passion is innovation®

MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.

More

Advanced Science 
Practical Design

We specialize in innovative technologies with proven ease-of-use and patient acceptance.

More

Patient-Friendly
Inhalation Treatments

Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.

More

In Partnership
Your Drug, Our Delivery.

Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.

More

About Us

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.  More

 

 

facebook-c_130x50      twitter_130x50

 

FDA Approved

For information about AFREZZA®,
please visit www.AFREZZA.com.

 

New Afrezza Website is Live

Afrezza®, the only inhaled rapid-acting mealtime insulin in the U.S. commercialized by MannKind, has launched a new website. The site includes a fresh design for easier access to the answers you need, a new blog feature, and an expanded FAQ list. For more information, visit www.afrezza.com

WARNING:


If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.

Close